3 Drugs Stocks Nudging The Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 69 points (-0.4%) at 18,094 as of Thursday, May 28, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 843 issues advancing vs. 2,162 declining with 143 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is down 0.4%. Top gainers within the industry include Gilead ( GILD), up 0.7%, and Mylan ( MYL), up 0.7%. On the negative front, top decliners within the industry include Novo Nordisk A/S ( NVO), down 1.2%, Celgene ( CELG), down 1.0%, Sanofi ( SNY), down 0.9% and Biogen ( BIIB), down 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Shire ( SHPG) is one of the companies pushing the Drugs industry higher today. As of noon trading, Shire is up $1.31 (0.5%) to $259.41 on average volume. Thus far, 338,241 shares of Shire exchanged hands as compared to its average daily volume of 618,200 shares. The stock has ranged in price between $257.82-$259.67 after having opened the day at $258.35 as compared to the previous trading day's close of $258.10.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. Shire has a market cap of $51.3 billion and is part of the health care sector. Shares are up 20.5% year-to-date as of the close of trading on Wednesday. Currently there are 9 analysts who rate Shire a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, compelling growth in net income and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Shire Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Eli Lilly and ( LLY) is up $0.94 (1.3%) to $75.84 on average volume. Thus far, 1.8 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 4.2 million shares. The stock has ranged in price between $74.74-$75.87 after having opened the day at $74.82 as compared to the previous trading day's close of $74.90.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. Eli Lilly and has a market cap of $82.5 billion and is part of the health care sector. Shares are up 8.6% year-to-date as of the close of trading on Wednesday. Currently there are 6 analysts who rate Eli Lilly and a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Actavis ( ACT) is up $4.66 (1.5%) to $311.45 on heavy volume. Thus far, 2.3 million shares of Actavis exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $308.41-$315.00 after having opened the day at $308.79 as compared to the previous trading day's close of $306.79.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Actavis plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic, branded generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. Actavis has a market cap of $117.8 billion and is part of the health care sector. Shares are up 19.2% year-to-date as of the close of trading on Wednesday. Currently there are 15 analysts who rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Actavis as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Actavis Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists